GB Sciences, Inc.

63 articles with GB Sciences, Inc.

• GB Sciences Welcomes Esteemed Patent and Intellectual Property Attorney, Mr. Edmond DeFrank, to Its Board of Directors

  10/31/2019

  GB Sciences, Inc. is pleased to announce that on October 23rd Mr. Edmond DeFrank joined its Board of Directors, filling a vacant seat.

• GB Sciences' Chief Science Officer Featured on the Cover of the Marijuana Business Magazine

  10/9/2019

  GB Sciences, Inc. (OTCQB: GBLX) is featured in the October 2019 edition of the Marijuana Business Magazine.

• GB Sciences Sells Its Louisiana Medical Marijuana Business At A $32 Million Total Valuation

  9/17/2019

  GB Sciences, Inc. (OTCQB: GBLX), on Friday, September 13, 2019, filed an 8k announcing the sale of its 50% ownership stake in GB Sciences Louisiana, LLC. 

• U.S. Drug Enforcement Agency to Expand Cannabis Research: GB Sciences Submitted One of Thirty-Three Applications to Become a DEA-Registered Cannabis Supplier to U.S. Marijuana Researchers

  9/3/2019

  GB Sciences, Inc. announced that it has received notification from the U.S. Drug Enforcement Agency that prior to making any decisions on the pending applications, the DEA intends to distribute regulations that govern the program of growing marijuana for scientific research under DEA registration.

• 

  BioSpace Movers & Shakers, Aug. 30

  8/30/2019

  Biopharma companies strengthen their leadership and boards with these appointments.

• GB Sciences Names Darin Carpenter as Executive Vice President of Cannabis Operations

  8/28/2019

  GB Sciences, Inc. announced the appointment to GB Sciences' executive team of Darin Carpenter as the company's new Executive Vice President for Operations and General Manager, bringing his extensive and nationally-recognized experience streamlining production, improving product quality, and increasing profitability to GBS.

• GB Sciences Files Novel Patent Application For Chronic Pain Treatments Based On Proprietary Cannabis-Derived Formulations

  7/17/2019

  In the US, chronic pain represents an estimated health burden of between $560 and $650 billion dollars.

• GB Sciences Obtains Exclusive License for Patented Oral Thin Film Technology Containing Cannabis and Hemp-Derived Ingredients

  6/11/2019

  Oral thin films provide a convenient and accurate delivery system with increased bioavailability of cannabis active ingredients for patients

• GBS Global Biopharma and National Research Council of Canada Begin Preclinical Studies on Chronic-Neuropathic Pain Therapies

  5/28/2019

  GBS Global Biopharma's proprietary neuropathic pain therapies are orally-delivered, time-released nanoparticles containing myrcene and other cannabinoid-based ingredients

• GB Sciences Louisiana Receives All Approvals and Announces the Opening of the Full Tissue Propagation Cannabis Cultivation at LSU Agricultural Center

  4/16/2019

  Increases production and ensures a continuous supply of therapeutic cannabis for Louisiana patients.

• Today: GB Sciences' Use of Controlled Cultivation, Product Formulations and Research Will Be Presented by Dr. Dominick Monaco at Cannabis Conference 2019, As Featured on Cover of Cannabis Business Times

  4/2/2019

  GB Sciences, Inc. announced that Dr. Dominick Monaco, GB Sciences' Director of Medical Formulations, will be a featured speaker at the Las Vegas Cannabis Conference, April 2, at 4:40pm.

• GB Sciences Study Shows Nevada's Cannabis Strain Names Have No Correlation to Active Ingredients

  3/28/2019

  What consumers see is not what they get: Study finds almost no chemical diversity in Nevada's cannabis varieties

• In Case You Missed It: GB Sciences Approved For Full Operations In Main LSU AgCenter Production Facility

  3/26/2019

  With over five times the production capacity, main facility will allow for a perpetual harvest cycle, ensuring a continuous supply of therapeutic cannabis for patients throughout Louisiana.

• GB Sciences Launches Global Expansion in Canada with GBS Global Biopharma, Inc.

  3/19/2019

  Expedites innovative cannabinoid medicine program, covering 60 disease and health conditions including Parkinson's Disease, neuropathic pain and cardiac hypertrophy

• GB Sciences Supports the Position of LSU AgCenter: Allegations Made by Commissioner Are Untrue

  3/12/2019

  LSU AgCenter issued the following statement on Friday, March 8th.

• GB Sciences Completes Harvest of First Cannabis Crop in Partnership with The Louisiana State University Agricultural Research Center

  1/16/2019

  Nationally recognized collaboration with the Louisiana State University Agricultural Center

• GB Sciences and The Colorado Hemp Project Sell First Hemp Crop for $0.7 Million Dollars

  12/12/2018

  Additionally, this first crop provides important seeds and genetics for future crops

• Exploring the Lesser Cannabinoids - The Happy Accident of CBN

  12/12/2018

  The following is from GB Sciences, Inc.'s (OTCQB: GBLX) "The Cannabis Brain Nurse," Meredith Patterson RN, BSN, CRRN: With or without a working knowledge of cannabis, most dispensary consumers have a speaking acquaintance with the compounds THC and CBD. 

• GB Sciences and Louisiana State University Agricultural Center Enter a Joint Research and Development Agreement for the Production of Therapeutic Cannabis Targeting Severe Medical Conditions and Diseases

  12/7/2018

  GB Sciences, Inc. (OTCQB: GBLX) announces on November 19, 2018, the Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, on behalf of the Louisiana State University Agricultural Center, entered into a Master Research and Development Agreement with GB Sciences Louisiana, LLC.

• GB Sciences Co-Authors a Peer-Reviewed Article Showing that Heart Failure Can Be Mitigated, and Reversed, by Orally Administered Drugs Targeting a Cellular Cannabinoid Receptor

  11/27/2018

  Pioneering new scientific research in the publication, Channels, explains the promise of targeting the ionotropic cannabinoid receptor TRPV1, for the treatment and reversal of heart failure.